KLRK1 and neoplasm: However, after binding, they cannot activate the downstream signaling pathway of NKG2D, and they cannot activate NK cells to exert the effect of killing tumor cells; these soluble ligands occupy the binding domain of NKG2D and MICA/B, which are expressed on tumor cells [50].